The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis

Zaharov V.V.; Vakhnina N.V.

doi:https://doi.org/10.17116/jnevro202412401182

Close metadata

OBJECTIVE

To conduct a meta-analysis of the effectiveness of Mexidol therapy in patients with chronic brain ischemia (CBI) and cognitive disorders (CD).

MATERIAL AND METHODS

This meta-analysis included the results of studies on the effectiveness of Mexidol in patients with CD measured with Montreal Cognitive Assessment Scale (MoCA). The pooled effect assessment included all publications from independent clinical trials that provided efficacy data on the MoCA scale with a level of detail sufficient for further mathematical analysis. The main result of the meta-analysis was obtained for the final values of the effectiveness indicator in the Mexidol groups compared with the basic therapy groups. Data from 10 prospective randomized trials containing information on the final scores on the MoCA scale after therapy was analyzed

RESULTS

The meta-analysis of ten prospective clinical studies of the effectiveness of Mexidol against the background of basic therapy in patients with CCI and CD was carried out. The total number of patients taking Mexidol was 482; the comparison group consisted of 455 patients. According to the results of a statistical model of random effects, the effect size was 2.06; 95% confidence interval for the difference in effectiveness between the groups of the study drug and the control groups [0.98; 3.14] (p=0.0002).

CONCLUSION

A statistically significant and clinically significant improvement in the cognitive functions of patients with CBI, was demonstrated after treatment with Mexidol.

Keywords:

chronic brain ischemia

cognitive impairment

ethylmethylhydroxypyridine succinate

Mexidol

treatment

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Vakhnina N.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-0834-4030

Received:

03.10.2023

Accepted:

04.10.2023

Close metadata

References:

Zakharov VV, Sleptsova KB, Martynova OO. Chronic cerebral ischemia: a view from the XXI century. RMJ. 2021;5:45-49. (In Russ.).
Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinic, treatment). M.: AST; 2018. (In Russ.).
Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Overall morbidity rate among the adult population of Russia in 2017. Statistical materials. Part 4. M. 2018;160 p. (Electronic resource). (In Russ.). Link available on 28.09. 2023. https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god
Clinical guidelines. Ischemic stroke and transient ischemic attack in adults. 2021. (In Russ.).
Lokshina AB, Zakharov VV. Practical algorithms for managing patients with chronic cerebral ischemia. Effektivnaya Farmakoterapiya. 2019;15(19):24-28. (In Russ.). https://doi.org/10.33978/2307-3586-2019-15-19-24-28
Guidelines for conducting meta-analysis. FSBI Center for Expertise and Quality Control of Medical Care. Ministry of Health of the Russian Federation, M. 2017. (In Russ.).
Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.).
Zhuravleva MV, Prokofiev AB, Serebrova SYu, et al. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(6):119-124. (In Russ.). https://doi.org/10.17116/jnevro2020120061119
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Voronina TA. Pioneer of antioxidant neuroprotection. 20 years in clinical practice. RMJ. 2016:7(24):434-438. (In Russ.).
Burdakov VV, Krasnykh DV. Efficacy and safety of ethylmethylhydroxypyridine succinate in sequential therapy in patients with chronic cerebral ischemia. Nevrologiya, Nejropsihiatriya, Psihosomatika. 2020;12(1):56-60. (In Russ.). https://doi.org/10.14412/2074-2711-2020-1-56-60
Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, et al. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. Insult. 2006;118(18):47-54. (In Russ.).
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Kashin AV. Efficacy and safety of mexidol in the treatment of cognitive dysfunction in patients with ischemic stroke. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;1:36-38. (In Russ.).
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Ger Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Chuang C, Chen C, Su KH, et al. The effects of high versus low frequency of combined physical and cognitive training on cognitive function in older adults with cognitive decline: a quasi-experimental study. BMC Geriatrics. 2023;23:94. https://doi.org/10.1186/s12877-023-03802-8
Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135-140. https://doi.org/10.1186/1471-2288-14-135
Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Shchepankevich LA, Nikolaev YuA, Taneeva EV, et al. The efficacy and safety study of Mexidol and Mexidol FORTE 250 in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10):32-37. (In Russ.). https://doi.org/10.17116/jnevro202112110132
Loskutnikov MA, Domashenko MA, Vakin TM, et al. The trial of the efficacy and safety of sequential therapy with Mexidol forte 250 in acute and early recovery stages of hemispheric ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(10):22-26. (In Russ.). https://doi.org/10.17116/jnevro202012010122
Bolotova EV, Lushpay TYu, Kovrigina IV. Improvement of the efficacy of treatment of hypertensive encephalohathy by using mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(4):61-64. (In Russ.). https://doi.org/10.17116/jnevro20181184161-64
Yanishevsky SN. Experience in the use of Mexidol in the treatment of chronic cerebrovascular insufficiency in patients with stenosing-occlusive lesions of the main brachycephalic vessels. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2006;5(1):159-163. (In Russ.).
Karpov SM, Morozova MYu, Muravyov KA, et al. Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(3-2):59-62. (In Russ.). https://doi.org/10.17116/jnevro202212203259
Strel’nikova IA, Svetkina AA, Androfagina OV. The efficacy and safety of Mexidol Forte 250 as part of long-term sequential therapy in patients with carotid stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(3-2):54-58. (In Russ.). https://doi.org/10.17116/jnevro202012003254
Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
Kuznetsova EB, Salina EA, Kuznetsov NS. Efficacy of Mexidol in the correction of postcovid syndrome in patients with chronic cerebrovascular diseases. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(5):117-122. (In Russ.). https://doi.org/10.17116/jnevro2023123051117
Kovalchuk VV, Ershova II, Molodovskaya NV. Possibilities of improving the effectiveness of therapy in patients with chronic cerebral ischemia against the background of COVID-19. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(3-2):60-66. (In Russ.). https://doi.org/10.17116/jnevro202112103260
Papadimitropoulou K, Riley RD, Dekkers OM, et al. MA-cont:pre/post effect size: An interactive tool for the meta-analysis of continuous outcomes using R Shiny. Research Synthesis Methods. 2022;13(5):649-660. https://doi.org/10.1002/jrsm.1592
Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (pre-dementia) stage. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12. (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo controlled study. Lancet Neurol. 2008;123(7):875-884.
Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology. 2009;72:1727-1234.
Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly: results of the PROSPER study. J Neurol. 2010;257:85-90.